Isaq NA, Link J. Response to Papp et al.'s "Long-Term Safety and Disease Control with Ruxolitinib Cream in Atopic Dermatitis: Results From Two Phase 3 Studies". J Am Acad Dermatol 2023 Sep 12:S0190-9622(23)02695.
PMID: 37708975